Free Trial

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Ascendis Pharma A/S logo
$174.96 -1.53 (-0.87%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$174.94 -0.02 (-0.01%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Key Stats

Today's Range
$173.78
$177.18
50-Day Range
$151.25
$179.10
52-Week Range
$111.09
$183.00
Volume
387,284 shs
Average Volume
505,812 shs
Market Capitalization
$10.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$223.07
Consensus Rating
Buy

Company Overview

Ascendis Pharma A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ASND MarketRank™: 

Ascendis Pharma A/S scored higher than 72% of companies evaluated by MarketBeat, and ranked 294th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ascendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ascendis Pharma A/S has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Ascendis Pharma A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ascendis Pharma A/S is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ascendis Pharma A/S is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Ascendis Pharma A/S's valuation and earnings.
  • Percentage of Shares Shorted

    6.16% of the float of Ascendis Pharma A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Ascendis Pharma A/S has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Ascendis Pharma A/S has recently decreased by 15.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ascendis Pharma A/S does not currently pay a dividend.

  • Dividend Growth

    Ascendis Pharma A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.16% of the float of Ascendis Pharma A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Ascendis Pharma A/S has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Ascendis Pharma A/S has recently decreased by 15.99%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ascendis Pharma A/S has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Ascendis Pharma A/S this week, compared to 7 articles on an average week.
  • Search Interest

    14 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Ascendis Pharma A/S's insider trading history.
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
ASND Ascendis Pharma A/S - Seeking Alpha
See More Headlines

ASND Stock Analysis - Frequently Asked Questions

Ascendis Pharma A/S's stock was trading at $137.67 at the beginning of the year. Since then, ASND stock has increased by 27.1% and is now trading at $174.96.

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by $0.10. The biotechnology company earned $123.97 million during the quarter, compared to the consensus estimate of $98.56 million.
Read the conference call transcript
.

Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Top institutional investors of Ascendis Pharma A/S include Harbor Capital Advisors Inc. (0.13%) and Diversified Trust Co (0.07%).

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/01/2025
Today
7/12/2025
Next Earnings (Estimated)
9/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ASND
CIK
1612042
Employees
1,017
Year Founded
N/A

Price Target and Rating

High Price Target
$289.00
Low Price Target
$153.00
Potential Upside/Downside
+27.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$409.12 million
Net Margins
-93.22%
Pretax Margin
-92.10%
Return on Equity
N/A
Return on Assets
-33.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.04
Quick Ratio
0.71

Sales & Book Value

Annual Sales
$393.54 million
Price / Sales
27.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.88) per share
Price / Book
-93.06

Miscellaneous

Outstanding Shares
61,130,000
Free Float
36,679,000
Market Cap
$10.70 billion
Optionable
Optionable
Beta
0.38

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ASND) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners